作者: Maciej Tarnowski , Agnieszka Paradowska-Gorycka , Ewa Dąbrowska-Zamojcin , Michal Czerewaty , Sylwia Słuczanowska-Głąbowska
DOI: 10.1517/17425255.2016.1121233
关键词:
摘要: Introduction: Rheumatoid arthritis (RA) is a systemic disease leading to joint destruction. The therapy of RA mainly based on disease-modifying anti-rheumatic drugs (DMARDs) and biological drugs. response treatment different among patients. Therefore, we have searched for factors that may predict the efficacy toxicity during in individual patients.Areas covered: This review presents role genetic polymorphisms as predictors patients with DMARDs (methotrexate, leflunomide, sulfasalazine) (anti-TNF-alpha antagonists, Tocilizumab, Rituximab).Expert opinion: Despite studies having shown an association between patients, majority these findings are still inconclusive inconsistent. We far from applying pharmacogenetic tests routine clinical practice can outcome treatment. Several factors, such small sample size...